share_log

Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $38

Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $38

Canaccord Genuity维持对Hims & Hers Health的买入评级,将价格目标上调至38美元
Benzinga ·  12/02 22:19  · 评级/大行评级

Canaccord Genuity analyst Maria Ripps maintains Hims & Hers Health (NYSE:HIMS) with a Buy and raises the price target from $28 to $38.

Canaccord Genuity分析师Maria Ripps维持Hims & hers Health(纽交所:HIMS)的买入评级,并将目标价格从28美元上调至38美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发